Neural/Glial Antigen 2 (NG2) Monoclonal Antibody (9.2.27), eBioscience™, Invitrogen™

Beschreibung

Description: This 9.2.27 monoclonal antibody reacts with human neural/glial antigen 2, which is also known as melanoma chondroitin sulfate proteoglycan (MCSP). This antigen is composed of a 250 kDa N-linked glycoprotein and a >450 kDa proteoglycan. NG2 is present on the surface of >90% of maligt melanomas in addition to some non-melanomic tumors. Moreover, NG2 is expressed on glioma cells, as well as on developing and adult oligodendrocyte precursor cells. Studies have demonstrated the involvement of this protein in tumor cell proliferation, adhesion, migration, and invasion. NG2 also functions as a coreceptor for alpha4beta1 integrin. Finally, expression of NG2 can be used as a prognostic marker for disorders such as acral letiginous melanoma and infantile acute myeloid leukemia. The 9.2.27 antibody has been reported to suppress melanoma tumor growth. Applications Reported: This 9.2.27 has been reported for use in flow cytometric analysis, immunoprecipitation, immunohistochemical staining of formalin-fixed paraffin embedded tissue (IHC-P), and immunocytochemical staining of fixed cells (ICC). Applications Tested: This 9.2.27 antibody has been tested by immunocytochemistry on methanol-fixed A375 cells at less than or equal to 10 μg/mL and by flow cytometric analysis on A375 cells at less than or equal to 0.125 μg/test. A test is defined as the amount (ug) of antibody that will stain a cell sample in a final volume of 100 μL.

A human melanoma-associated chondroitin sulfate proteoglycan plays a role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes. CSPG4 represents an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells.